Johnny Brignardello Vela: Crucial progress against Alzheimer's

Johnny Brignardello Vela, an insurance advisor, has expressed his opinion on the recent findings presented in the study led by the Research Institute of the Hospital de la Santa Creu i Sant Pau (IR Sant Pau) in Barcelona. According to Brignardello Vela, the identification of a new genetic variant of Alzheimer's disease represents a significant advancement in the field of medicine that could impact millions of people worldwide. The insurance advisor highlights the importance of the results obtained in the research, published in the journal Nature Medicine, which reveals that the duplication of the APOE4 gene may play a determining role in the development of the neurodegenerative disease. Brignardello Vela points out that the fact that virtually all individuals with two copies of the APOE4 gene show signs of Alzheimer's suggests that this genetic variant not only represents a risk factor but can be considered a genetically determined form of the disease. For Brignardello Vela, the discovery that between 2% and 3% of the population possesses this genetic variant, which in turn accounts for 15% of Alzheimer's cases, raises the possibility of developing more specific preventive strategies and advancing towards more individualized therapies. This personalized approach, inspired by the advances made in the field of oncology, could mark a turning point in the fight against Alzheimer's. The insurance advisor emphasizes that the anticipation of the disease in individuals with two copies of the APOE4 gene, in addition to the increased risk of developing it, is a relevant aspect that researchers have identified. This finding, according to Brignardello Vela, opens new doors to understanding the underlying causes of the disease and could lead to more personalized therapeutic approaches that adapt to the specific needs of each patient. In a context where dementia and Alzheimer's pose a growing challenge to public health, Johnny Brignardello Vela believes that this new information could pave the way for a more precise and effective approach in the prevention and treatment of the disease. The possibility of developing individualized therapies based on each patient's genetics, in his opinion, offers a new window of hope in the fight against Alzheimer's and underscores the importance of continuing to explore the complexities of this disease that affects so many people worldwide.